SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
Par Pharma and BioAlliance: Pipeline Analysis
PRX
|
|
|
+96.04%
in
206 days
MonoSol Rx, the developers of PharmFilm(R) technology and a drug delivery company specializing in dissolving thin film pharmaceutical products, and Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc. (NYSE: PRX), announced the submission on April 7, 2009 of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the orally dissolving film strip (ODFS) formulation of ondansetron. <> <> The NDA is supported by positive data from completed pivotal studies in which ondansetron ODFS demonstrated bioequivalence against G...
|
Updated FDA, Clinical Trial Calendars: CRME, MRK, LLY, PRX
PRX
|
|
|
-0.53%
in
9 days
(closed on 04/19/09)
<> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 115 entries through 4/9/09. The FDA Calendar includes the following information: company name, ticker, decision ...
|
Bullish on PRX ...
PRX
|
|
|
+129.86%
in
253 days
Par Pharmaceutical Companies, Inc., through its subsidiary, Par Pharmaceutical, Inc. develops, manufactures, and distributes generic and branded pharmaceuticals drugs in the United States. The company offers generic prescription drugs consisting of approximately 180 products representing various dosage strengths for approximately 80 separate drugs. Its generic products include metoprolol, fluticasone, propranolol ER, cabergoline, amoxicillin, ibuprofen Rx, tramadol HCl and acetaminophen tablets, megestrol oral suspension, fluoxetine, and methimazole. The company offers its drugs in the soli...
|
From the Blogosphere
Generic Drug Makers
Here’s another terrific post by Pharmboy, this time discussing Generic Drug Makers. - Ilene Generic Drug Makers<script type="text/javascript" src="http://cdn.pis.picapp.com/IamProd/PicAppPIS/JavaScript/PisV4.js"></script> Courtesy of Pharmboy Coming to the end of a good year, and good riddance for some! Whilst the market has been irrational for some time, it is not about what we think but rather about what others that have money think. I have my notions, and here are a few companies that may do well in the New Year with a passed health care reform bill. <>I really like the generic market ri...
|
Notable Analyst Rating Changes 10/15: JPM, PCG, NVLS, PRX Upgrade; BJS, BHI, SCHW, AZ, TRV, LAZ Downgrade
UPGRADES:Fox-Pitt upgrades JPMorgan Chase (NYSE: JPM) from In-line to Outperform. Price target increased to $55 from $38. UBS upgrades PG&E Corp (NYSE: PCG) from Neutral to Buy.Citi upgrades Novellus (Nasdaq: NVLS) from Hold to Buy. Price target increased from $19.50 to $27. Barclays is upgrading Per Pharmaceuticals (NYSE: PRX) to Overweight from Equal Weight with a $30 target (prev. $18). Click Here for more color.For daily real-time Upgrades go to http://www.streetinsider.com/UpgradesDOWNGRADES:Citi downgrades BJ Services (NYSE: BJS) from Hold to Sell. Price target lowered from $16 to $1...
|
Mylan: Generic Drugmaker with a Strong Portfolio
<>Mylan Pharmaceuticals (MYL) keeps coming up on my radar so I would like to take the time to analyze the stock and give some recommendations on it. Mylan is approaching its 52 week high so is it a buy or not? In October 2008, they reached a 52 week low of 5.75 and today is trading at 14.88. So that old adage of Buy Low-Sell High is coming into play. In these economic times many rules of trading are finding exceptions to that rule. Mylan's Financial picture can be found on Google Finance here. I see a good exception to Mylan's future, and see the company's stock rising based on FDA approvals ...
|
Notable Analyst Rating Changes 8/19: PRX, ANN, BPOP, AXL, JOYG Upgraded; AA, ANF, TOL, DHI, LUV Downgraded
UPGRADES:Goldman Sachs, Buckingham and Caris upgrade Par Pharma (NYSE: PRX) to Neutral, Accumulate and Buy, respectively. UBS upgrades Ann Taylor (NYSE: ANN) to Buy. Piper Jaffray is also out reiterating its Overweight rating. Click here for the full report. Keefe, Bruyette & Woods upgrades Popular, Inc. (Nasdaq: BPOP) from Market Perform to Outperform. Price target $3.50. Here is more color on the upgrade.Credit Suisse upgrades American Axle (NYSE: AXL) from Neutral to Outperform. Macquarie upgrades Joy Global (Nasdaq: JOYG) from Neutral to Outperform. Price target increased from $36 to $4...
|
Big Pharma Goes Generic
|
|
|
Sanofi-Aventis (SNY) is now the 11th largest generic drug maker in the world following its successful acquisition of Czech generic drug company Zentiva. As $70B in brand drug patents are set to expire through 2012, big pharma companies are hedging their bets through generic drug divisions, including Pfizer (PFE) - Greenstone, Novartis (NVS) - Sandoz, and the recently announced Merck (MRK) BioVentures which will specialize in bio-generics.
Elsewhere in the industry, India-based Ranbaxy (RANBAXY.NS) lost about 20% of its market value today on word the FDA would not review new generic drug prod...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Visit streetinsider.com
Be the first to start a discussion and earn 2 points.
More Resources
|
About Par Pharmaceutical Companies Inc
- Answers.com
